Form 4: Rapport Therapeutics CEO Sells Shares Via 10b5-1 Plan

Rapport Therapeutics CEO Abraham Ceesay sold 10,916 shares of common stock for approximately $281,930 through pre-arranged 10b5-1 trading plans.

Summary

• Abraham Ceesay, Chief Executive Officer and Director of Rapport Therapeutics, Inc. (RAPP), sold a total of 10,916 shares of common stock on October 15, 2025.
• The transactions were executed pursuant to Rule 10b5-1 trading plans that were adopted on December 12, 2024.
• The shares were sold at weighted average prices ranging from $25.724 to $26.1721 per share.
• The estimated total proceeds from these sales amounted to approximately $281,930.
• Following these transactions, Abraham Ceesay directly owns 579,579 shares and indirectly owns 41,061 shares through The Dorothy Ceesay Irrevocable Trust and 81,729 shares through The Ceesay Family Irrevocable Trust.

Sentiment

Score: 4

Explanation: While insider sales can be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates some of the concern, suggesting a planned liquidity event rather than a lack of confidence in the company's future. However, it still represents a reduction in insider ownership.

Positives

• The sales were conducted under pre-arranged Rule 10b5-1 trading plans, indicating a planned divestment strategy rather than a reaction to new, potentially negative, company information.

Negatives

• An insider sale by the CEO and a Director, even if pre-planned, can sometimes be perceived by the market as a negative signal regarding future stock performance.
• The transactions resulted in a reduction of both direct and indirect beneficial ownership by a key executive.

Risks

• Potential negative market perception due to insider selling, which could exert downward pressure on the company's stock price.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The Reporting Person disclaims beneficial ownership of shares held by The Dorothy Ceesay Irrevocable Trust and The Ceesay Family Irrevocable Trust for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), except to the extent of his pecuniary interest therein, if any.
• This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Industry Context

This Form 4 filing reports an insider transaction and does not provide information related to broader industry trends or the competitive landscape.

Related Party Transactions

• Sales of 4,328 shares and 755 shares were made indirectly through The Dorothy Ceesay Irrevocable Trust, an entity related to the CEO.
• The Ceesay Family Irrevocable Trust also holds shares indirectly beneficially owned by the CEO.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal, potentially influencing market sentiment, though the pre-arranged 10b5-1 plan lessens the impact.
• The CEO's ownership stake is reduced, but a significant portion remains, maintaining alignment of his interests with shareholders.

Key Dates

Recommendation

The sale of shares by CEO Abraham Ceesay, while notable, was conducted under a pre-arranged 10b5-1 trading plan, which typically indicates a planned liquidity event rather than a reaction to new, adverse company information. This mitigates the negative signal often associated with insider selling. Given the absence of other significant company-specific news in this filing, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while monitoring for further operational or financial updates from Rapport Therapeutics.

Keywords

Rapport Therapeutics, RAPP, Insider Trading, Form 4, Abraham Ceesay, CEO, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals